Neuraxis, INC 8-K

What Happened
Neuraxis, Inc. (NRXS) filed an 8-K on April 22, 2026 announcing an amendment to its At-The-Market (ATM) offering arrangement with Craig‑Hallum Capital Group LLC. The company originally entered the ATM agreement on August 29, 2025 with an aggregate offering amount of up to $6,270,000; on April 21, 2026 it filed a prospectus supplement increasing the available amount to $11,500,000. Neuraxis reported that, under the agreement, it sold 1,125,281 shares of common stock from August 29, 2025 through April 20, 2026. Sales are made under the company’s effective Form S-3 registration (File No. 333-283798).

Key Details

• Sales agent: Craig‑Hallum Capital Group LLC under an ATM agreement entered August 29, 2025.
• Shares sold to date: 1,125,281 shares sold under the ATM through April 20, 2026.
• Offering capacity: increased from $6,270,000 to $11,500,000 (prospectus supplement filed April 21, 2026).
• Legal opinion: Lucosky Brookman LLP’s opinion regarding the issuance/sale is attached as Exhibit 5.1 to the 8-K.

Why It Matters
An expanded ATM gives Neuraxis flexibility to raise up to $11.5 million over time by selling shares into the market at its discretion. For investors, this can mean potential dilution if the company sells additional shares, but it also provides a ready mechanism for management to access capital for operations, development, or other needs without a single large offering. The 8‑K documents past share sales and formalizes the increased capacity; it does not itself constitute an offer to buy or sell securities.